MRSA Prevention: Can Mupirocin Help

Why does the CDC's COVID-19 review highlight infection prevention?

The CDC reports that hospital-onset infections and deaths involving seven antimicrobial-resistant pathogens increased by at least 15% from 2019 to 2020. Contributing pressures included longer hospital stays, greater use of invasive devices, staffing shortages and disrupted infection-control practices. These are historical pandemic findings, not estimates of a new surge in October 2026. [CDC pandemic assessment](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/covid-19.html).

One practical concern is methicillin-resistant Staphylococcus aureus, or MRSA. People can carry these bacteria without symptoms and still transmit them. Surgery and medical devices increase infection risk, and serious MRSA infections can involve the bloodstream, lungs or surgical wounds. This distinction between carrying bacteria and developing an infection creates an opportunity for preventive treatment. [CDC clinical overview](https://www.cdc.gov/mrsa/hcp/clinical-overview/index.html).

How effective are mupirocin and chlorhexidine after discharge?

The randomized CLEAR trial, published in the New England Journal of Medicine in 2019, studied adults carrying MRSA after hospitalization. Participants received hygiene education alone or education plus nasal mupirocin, chlorhexidine bathing and chlorhexidine mouthwash. Treatment occurred for five days twice monthly over six months, with follow-up lasting one year. [CLEAR trial](https://www.nejm.org/doi/full/10.1056/NEJMoa1716771).

In the main analysis, MRSA infection occurred in 9.2% of the education group and 6.3% of the decolonization group, an absolute difference of 2.9 percentage points. The reported 30% reduction describes the relative infection hazard. Because researchers tested a combination, the findings cannot establish how much benefit came from mupirocin alone. The trial was unblinded, although infection outcomes underwent blinded review. [Trial methods and results](https://www.nejm.org/doi/full/10.1056/NEJMoa1716771).

Who should consider MRSA decolonization?

Decolonization means reducing bacteria carried on the body. Nasal mupirocin targets a reservoir of Staphylococcus aureus, while chlorhexidine products reduce bacteria at other treated sites. CDC researchers describe this approach as one component of preventing healthcare-associated infections. Appropriate patient selection matters because antimicrobial exposure can also select for resistance, and different settings require different protocols. [CDC researchers' review](https://wwwnc.cdc.gov/eid/article/30/6/23-1338_article).

A prevention plan must also distinguish colonization from active disease. A painful, swollen or draining skin lesion, particularly with fever, needs clinical assessment. An abscess may require drainage, and some infections require antibiotics selected according to the clinical situation and laboratory results. Preventive topical products do not provide adequate treatment for an established bloodstream infection or pneumonia. [CDC treatment guidance](https://www.cdc.gov/mrsa/hcp/clinical-overview/index.html).